| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/09/2003 | US20030008390 Genetically engineered cell for use in the generation of viral vector for use in gene therapy |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2452171A1 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | CA2452092A1 Carbohydrate derivatives |
| 01/09/2003 | CA2452030A1 Sustained release pharmaceutical composition |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273575A1 Diazepane derivatives or salts thereof |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272853A2 Methods for identifying and using amyloid-inhibitory compounds |
| 01/08/2003 | EP1272670A2 Diagnosis of diseases associated with dna adducts |
| 01/08/2003 | EP1272527A2 Anti-d monoclonal antibodies |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272505A1 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives |
| 01/08/2003 | EP1272504A1 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/08/2003 | EP1272489A1 Process for preparing crystalline form i of cabergoline |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272483A2 OXINDOLE INHIBITORS OF FACTOR Xa |
| 01/08/2003 | EP1272474A1 Substituted 5-methyldihydropyridazinones and their use in the prophylaxis and/or treatment of anemias |
| 01/08/2003 | EP1272470A1 Amorphous torasemide modification |
| 01/08/2003 | EP1272458A1 Arginine mimetics as factor xa inhibitors |
| 01/08/2003 | EP1272457A2 Compounds for modulating cell proliferation |
| 01/08/2003 | EP1272217A1 Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease |
| 01/08/2003 | EP1272201A2 Use of compatible solutes as substances having free radical scavenging properties |
| 01/08/2003 | EP1272178A2 Bilirubin or biliverdin degradation fragments |
| 01/08/2003 | EP1272175A2 Il-8 receptor antagonists |
| 01/08/2003 | EP1272168A2 Small organic molecule regulators of cell proliferation |
| 01/08/2003 | EP1272167A1 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 01/08/2003 | EP0984934B1 Novel orally active iron (iii) chelators |
| 01/08/2003 | EP0833839B1 Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| 01/08/2003 | CN1390258A Factor IX/factor IXa antibodies and antibody derivatives |
| 01/08/2003 | CN1390253A High order nucleic acid based structures |
| 01/08/2003 | CN1390222A Imidazole compounds used as phosphodiesterase VII inhibitors |
| 01/08/2003 | CN1390220A Kinase inhibitors as therapeutic agents |
| 01/08/2003 | CN1390219A Pyrazolopyrimidines as therapeutic agents |
| 01/08/2003 | CN1390206A Inhibitors of factor Xa |
| 01/08/2003 | CN1390196A Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 01/08/2003 | CN1390128A Use of adatanserin for treating neurogenerative disorders |
| 01/08/2003 | CN1390122A Tissue factor antagonists and methods of use thereof |
| 01/08/2003 | CN1390118A Dextrose and insulin fluid formulation for intravenous infusion |
| 01/08/2003 | CN1098256C Substd. benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors |
| 01/08/2003 | CN1098103C Pharmaceutical use of sympathetic human white-cell interferon |
| 01/07/2003 | US6504030 Polymorphic form of clopidogrel hydrogen sulphate |
| 01/07/2003 | US6504011 Recombinantly produced serum albumin is purified in a series of steps, optionally by incubation with an anion-exchange adsorbent, followed by affinity chromatography employing a hydrophobic solid phase and using a water-soluble lipid anion |
| 01/07/2003 | US6503934 Substituted thiadiazolesulfonamides |
| 01/07/2003 | US6503930 Pyrazole derivatives as p38 kinase inhibitors |
| 01/07/2003 | US6503914 Thienopyrimidine-based inhibitors of the Src family |
| 01/07/2003 | US6503910 Hydroxamic and carboxylic acid derivatives |
| 01/07/2003 | US6503713 Methods for identifying RNA binding compounds |
| 01/07/2003 | CA2220923C Process of high purity albumin production |
| 01/07/2003 | CA2113363C Process for constructing a cdna library and a novel polypeptide and dna coding the same |
| 01/07/2003 | CA2075590C Hydantoin derivatives |
| 01/05/2003 | CA2390181A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/03/2003 | WO2003000896A2 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 01/03/2003 | WO2003000864A2 Nucleic acid-associated proteins |
| 01/03/2003 | WO2003000736A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/03/2003 | WO2003000694A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 01/03/2003 | WO2003000691A1 Carboline derivatives as pdev inhibitors |
| 01/03/2003 | WO2003000684A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | WO2003000680A1 Diamine derivatives |
| 01/03/2003 | WO2003000677A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | WO2003000671A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | WO2003000657A1 Diamine derivatives |
| 01/03/2003 | WO2003000653A1 Substituted n-acyl aniline derivatives, production and use thereof as medicaments |
| 01/03/2003 | WO2003000649A1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | WO2003000258A1 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | WO2003000256A1 Substituted oxazolidinones for combinational therapy |
| 01/03/2003 | WO2003000253A1 Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | WO2003000242A2 Method for the treatment of lymphedema using guaifenesin |
| 01/03/2003 | WO2003000238A1 Pharmaceutical compositions of adsorbates of amorphous drug |
| 01/03/2003 | WO2003000185A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | WO2003000181A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000179A2 Chemically-modified progenipoietin conjugates |
| 01/03/2003 | WO2003000178A2 Black soybean polysaccharides |
| 01/03/2003 | WO2002087605A3 Modified fvii in treatment of ards |
| 01/03/2003 | WO2002085353A9 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor xa inhibitors |
| 01/03/2003 | WO2002083667A3 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/03/2003 | WO2002080914A3 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments |
| 01/03/2003 | WO2002072584A3 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 01/03/2003 | WO2002070594A3 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 01/03/2003 | WO2002069960A3 Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002009761A3 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | WO2002000193A3 Multiple stimulus reversible hydrogels |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450950A1 Chemically-modified progenipoietin conjugates |